Shanghai Bio-heart Biological Technology Co., Ltd.
2185
Rank in Stocks
#25052
Based in the People's Republic of China, Shanghai Bio-heart Biological... Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies to address conditions like coronary artery diseases and persistent, uncontrolled high blood pressure. The company's product pipeline features Bioheart, a BRS system designed for percutaneous coronary interventions for coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and a sirolimus drug-eluting balloon catheter intended for managing in-stent restenosis. Furthermore, the company has partnered with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was established in 2014 and maintains its headquarters in Shanghai, China.
Share Price
$0.11472589
Last synced: 2026-11-13
Market Cap
$27.93M
Change (1 day)
-4.25%
Change (1 year)
-88.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Shanghai Bio-heart Biological Technology Co., Ltd. (2185)
Category
Healthcare
Operating Margin for Shanghai Bio-heart Biological Technology Co., Ltd. (2185)
Operating Margin as of November 2026 TTM: -228.91%
According to Shanghai Bio-heart Biological Technology Co., Ltd.'s latest financial reports, its current operating margin (TTM) is -228.91%. At the end of 2025 the company had an operating margin of -159.56%.
Operating Margin history for Shanghai Bio-heart Biological Technology Co., Ltd. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -228.91% | 43.46% |
| 2025 | -159.56% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -99.15% |
US
|
|
| 33.87% | -100.15% |
US
|
|
| -116.04% | -99.49% |
US
|
|
| 25.57% | -100.11% |
AU
|
|
| 31.23% | -100.14% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Shanghai Bio-heart Biological Technology Co., Ltd.'s operating margin
What is Shanghai Bio-heart Biological Technology Co., Ltd.'s operating margin?
Shanghai Bio-heart Biological Technology Co., Ltd.'s operating margin is -228.91%, as of Nov 2026.
What was Shanghai Bio-heart Biological Technology Co., Ltd.'s operating margin in 2025?
In 2025, Shanghai Bio-heart Biological Technology Co., Ltd.'s operating margin was -159.56%, compared with 0.00% in 2024.
How has Shanghai Bio-heart Biological Technology Co., Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Shanghai Bio-heart Biological Technology Co., Ltd.'s operating margin was highest in 2024 (0.00%) and lowest in 2025 (-159.56%).
How does Shanghai Bio-heart Biological Technology Co., Ltd.'s operating margin compare with similar companies?
Shanghai Bio-heart Biological Technology Co., Ltd.'s operating margin (-228.91%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.